Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.

Παρόμοια τεκμήρια

• Letter: SARS‐CoV‐2 infection in two inflammatory bowel disease patients treated with dual targeted therapy—Authors' reply
  ανά: Al‐Ani, Aysha H., κ.ά.
  Έκδοση: (2021)
• Managing COVID‐19 in patients with inflammatory bowel disease: navigating unprecedented challenges
  ανά: Prentice, Ralley E., κ.ά.
  Έκδοση: (2021)
• Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
  ανά: Zingone, Fabiana, κ.ά.
  Έκδοση: (2020)
• Practical management of inflammatory bowel disease patients during the COVID‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty
  ανά: Aysha, Al‐Ani, κ.ά.
  Έκδοση: (2020)
• Letter: Covid‐19—re‐initiating clinical services for chronic gastrointestinal diseases. How and when? Authors' reply
  ανά: Prentice, Ralley E., κ.ά.
  Έκδοση: (2020)